Introducing MAD7

With a name inspired by the biological diversity found on the island of Madagascar, MADzymes have improved features such as different PAM recognition sequences, different cut efficiencies, reduced sizes, and different enzyme kinetics.

By developing and broadly releasing these enzymes, Inscripta strives to promote widespread exploration and adoption of CRISPR tools in both academic and commercial settings.

Inscripta has now released the DNA sequence of a first enzyme, MAD7, from its nuclease discovery and engineering platform, that is royalty-free for all R&D use.

Bespoke MADzyme development

As part of its business offerings, Inscripta will also be offering bespoke editing nucleases to commercial partners.

Interested in a custom CRISPR nuclease? Please inquire.